This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Astex Scientists Publish The Discovery Of Novel Allosteric Modulators For The Key Therapeutic Targets HCV NS3 And PKM2 In Nature Journals

Stocks in this article: ASTX

DUBLIN, Calif., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that Astex scientists have published two new articles describing the discovery of novel allosteric modulators for the key therapeutic targets HCV NS3 and PKM2 in Nature Journals.

Astex Pharmaceuticals used the company's leading fragment-based drug discovery platform, Pyramid™, to identify, in two separate studies, new allosteric pockets on the HCV NS3 protein and the PKM2 protein involved in tumor metabolism. The study on HCV NS3 which has just been published in Nature Chemical Biology 1 highlights the discovery of a novel allosteric pocket situated between the protease and helicase domains of the NS3 protein. It also describes how Astex scientists exploited this pocket to develop novel, first-in-class inhibitors of the HCV NS3 protein that interact with both the protease and helicase domains. A drug candidate from this program is due to enter clinical trials during 2013.

In the second study, now published in Nature 2, the Pyramid platform was used to identify a novel allosteric pocket on the tumor metabolism target PKM2 and unravel the role of serine on the function of this key cancer target. This novel allosteric pocket provides a new opportunity to discover allosteric modulators of PKM2 that could be developed into anti-cancer agents.

Dr. Harren Jhoti, president and director of Astex Pharmaceuticals, commented, "These two studies published in the leading Nature Journals underline the preeminent position Astex retains in using fragment-based drug discovery to identify novel drug candidates against technically challenging targets. We continue to develop the fragment-discovery platform to address more intractable drug targets, not only allosteric pockets but also protein-protein interactions, in our drive to develop new medicines for patients."

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals co-developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales from Eisai in North America and from Janssen-Cilag in the rest of the world.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,884.56 +79.76 0.45%
S&P 500 2,072.49 +1.84 0.09%
NASDAQ 4,773.1340 +7.7540 0.16%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs